Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.67 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GGT1 | P19440 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL4534925 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL7250097 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1939134 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL3677210 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL21328428 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1457620 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL26228 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL2157062 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL191054 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL24830 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | AMGEN INC. | 2009-12-17 | — | — | US | claimed |
| EP-2066774-A1 | WAREWASHING COMPOSITION FOR USE IN AUTOMATIC DISHWASHING MACHINES, AND METHOD FOR USING | ECOLAB INC. (US) | 2009-06-10 | — | — | EP | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1885348-A2 | ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE | Amgen, Inc (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2008013746-A1 | WAREWASHING COMPOSITION FOR USE IN AUTOMATIC DISHWASHING MACHINES, AND METHOD FOR USING | ECOLAB INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-20080020960-A1 | Warewashing composition for use in automatic dishwashing machines, and method for using | ECOLAB USA INC. | 2008-01-24 | — | — | US | claimed |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | AMGEN INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006124753-A2 | ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE | AMGEN INC. (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1684725-A1 | NOVEL NIMESULIDE COMPOSITIONS | Elan Pharma International Limited (IE) | 2006-08-02 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-6071417-A | ADDITION OF ALKALI POLYPHOSPHATES TO AN AQUEOUS SOLUTION CONTAINING RESIDUAL AMOUNTS OF CATIONIC, ANIONIC, OR AMPHOTERIC WATER-SOLUBLE MACROMOLECULAR COMPOUNDS, FORMATION OF INSOLUBLE COMPLEXES OF THE ALKALI POLYPHOSPHATE | KURITA WATER INDUSTRIES, LTD. (JP) | 2000-06-06 | — | — | US | claimed |
| EP-0957919-A1 | ANALGESIC COMPOSITION FOR TREATMENT OF MIGRAINE HEADACHES | Mauskop, Alexander (US) | 1999-11-24 | — | — | EP | claimed |
| US-5914129-A | MAGNESIUM SALT, STIMULANT, EFFERVESCING AGENT AND CARRIERS | MAUSKOP ALEXANDER (US) | 1999-06-22 | — | — | US | claimed |
| WO-1998003179-A1 | ANALGESIC COMPOSITION FOR TREATMENT OF MIGRAINE HEADACHES | MAUSKOP ALEXANDER (US) | 1998-01-29 | — | — | WO | claimed |
| US-4849417-A | ANALGESIC, ANTIPYRETIC | RHONE-POULENC SANTE (FR) | 1989-07-18 | — | — | US | claimed |
| US-4764637-A | Hydrated magnesium acetylsalicylate/urea complex preparation | RHONE-POULENC SANTE (FR) | 1988-08-16 | — | — | US | claimed |
| EP-0200628-B1 | DERIVATIVE OF ACETYLSALICYLIC ACID, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | RHONE-POULENC SANTE (FR) | 1988-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | VRK1, VIPR1, AVPR1A | PTGS2 777/4885PTGS1 247/4885KDM4E 4666/4885 |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | VRK1, VIPR1, AVPR1A | PTGS2 777/4885PTGS1 247/4885KDM4E 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.